MV-130(MV-130) - _专利_临床

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗

别名

BACTEK-R、Bacmune、Bactek

+ [3]

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

新型冠状病毒感染慢性阻塞性肺疾病

原研机构

Inmunotek SL

在研机构

Inmunotek SL

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 MV-130 相关的临床试验

PACTR202403820001276 / Suspended临床2期

The Influence of MV130 immunotherapy on Nasal Colonisation in a Controlled Human Infection Model of Pneumococcal Carriage in Malawi

开始日期2024-04-02

申办/合作机构

Liverpool School of Tropical Medicine

NCT05208060 / Recruiting临床1/2期

A Phase I/II Randomized, Prospective, Double-blind, Placebo-controlled, Single-center Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

A mechanistic clinical trial with the aim to evaluate whether MV130 can induce the expression of a particular immune response (trained immunity) in peripheral blood cells. Therefore, the investigators are not evaluating efficacy in any disease or medical condition but rather assessing the immunological effect in immunogenicity of MV130 in healthy volunteers.

开始日期2023-09-01

申办/合作机构

Inmunotek SL

NCT04452643 / Withdrawn临床3期

Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to SARS-CoV-2 Infection in Healthcare Personnel

The purpose of this trial is to assess the effect of immunotherapy with the bacterial preparation MV130 on the spread and course of SARS-CoV-2 infection in highly exposed subjets, as is the case with healthcare personnel.

开始日期2020-10-01

申办/合作机构

Inmunotek SL

100 项与 MV-130 相关的临床结果

登录后查看更多信息

100 项与 MV-130 相关的转化医学

登录后查看更多信息

100 项与 MV-130 相关的专利（医药）

登录后查看更多信息

12

项与 MV-130 相关的文献（医药）

2023-01-01·Frontiers in immunology

Combining different bacteria in vaccine formulations enhances the chance for antiviral cross-reactive immunity: a detailed in silico analysis for influenza A virus.

Article

作者: Lafuente, Esther M ; Ras-Carmona, Alvaro ; Reche, Pedro A ; Subiza, Jose L ; Bodas-Pinedo, Andrés ; Pelaez-Prestel, Hector F

Bacteria are well known to provide heterologous immunity against viral infections through various mechanisms including the induction of innate trained immunity and adaptive cross-reactive immunity. Cross-reactive immunity from bacteria to viruses is responsible for long-term protection and yet its role has been downplayed due the difficulty of determining antigen-specific responses. Here, we carried out a systematic evaluation of the potential cross-reactive immunity from selected bacteria known to induce heterologous immunity against various viruses causing recurrent respiratory infections. The bacteria selected in this work were Bacillus Calmette Guerin and those included in the poly-bacterial preparation MV130: Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Klebisella pneumoniae, Branhamella catarrhalis and Haemophilus influenzae. The virus included influenza A and B viruses, human rhinovirus A, B and C, respiratory syncytial virus A and B and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Through BLAST searches, we first identified the shared peptidome space (identity ≥ 80%, in at least 8 residues) between bacteria and viruses, and subsequently predicted T and B cell epitopes within shared peptides. Interestingly, the potential epitope spaces shared between bacteria in MV130 and viruses are non-overlapping. Hence, combining diverse bacteria can enhance cross-reactive immunity. We next analyzed in detail the cross-reactive T and B cell epitopes between MV130 and influenza A virus. We found that MV130 contains numerous cross-reactive T cell epitopes with high population protection coverage and potentially neutralizing B cell epitopes recognizing hemagglutinin and matrix protein 2. These results contribute to explain the immune enhancing properties of MV130 observed in the clinic against respiratory viral infections.

2022-01-01·Cell Reports1区 · 生物学

Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections

1区 · 生物学

ArticleOA

作者: Nieto, Antonio ; Amores-Iniesta, Joaquín ; Relaño, Carlos ; Del Fresno, Carlos ; Brandi, Paola ; Saz-Leal, Paula ; Ardavín, Carlos ; Dopazo, Ana ; Cueto, Francisco J ; Dunphy, Gillian ; Enamorado, Michel ; Casanovas, Miguel ; Sancho, David ; Quintas, Ana ; Martínez-Cano, Sarai ; Conejero, Laura ; Gómez, Manuel J ; Nistal-Villán, Estanislao ; Subiza, José Luis

MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients against recurrent respiratory infections, including those of viral etiology. However, its mechanism of action remains poorly understood. Here, we find that intranasal prophylaxis with MV130 modulates the lung immune landscape and provides long-term heterologous protection against viral respiratory infections in mice. Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking functional lymphocytes, indicative of innate immune-mediated protection. Moreover, pharmacological inhibition of trained immunity with metformin abrogates the protection conferred by MV130 against influenza A virus respiratory infection. MV130 induces reprogramming of both mouse bone marrow progenitor cells and in vitro human monocytes, promoting an enhanced cytokine production that relies on a metabolic shift. Our results unveil that the mucosal administration of a fully inactivated bacterial vaccine provides protection against viral infections by a mechanism associated with the induction of trained immunity.

2021-08-15·American Journal of Respiratory and Critical Care Medicine1区 · 医学

Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial

1区 · 医学

Article

作者: Fernández-Pérez, Cristina ; Calderón, Rafael ; Subiza, José Luis ; Casanovas, Miguel ; Conejero, Laura ; Uixera, Sonia ; Palao, Maria José ; Sancho, David ; Mazón, Angel ; Calaforra, Susana ; Brandi, Paola ; Selva, Blanca ; Nieto, María ; Saz-Leal, Paula ; Nieto, Antonio

Rationale: Recurrent wheezing in children represents a severe public health concern. Wheezing attacks (WA), mainly associated with viral infections, lack effective preventive therapies. Objectives: To evaluate the efficacy and safety of mucosal sublingual immunotherapy based on whole inactivated bacteria (MV130) in preventing WA in children. Methods: A Phase 3 randomized, double-blind, placebo-controlled, parallel-group trial including a cohort of 120 children <3 years old with ⩾3 WA during the previous year was conducted. Children with a positive skin test to common aeroallergens in the area where the clinical trial was performed were excluded from the trial. Subjects received MV130 or placebo daily for 6 months. The primary endpoint was the number of WA within 1 year after the first dose comparing MV130 and placebo. Measurements and Main Results: There was a significant lower number of WA in MV130 versus the placebo group, 3.0 (interquartile range [IQR], 2.0-4.0) versus 5.0 (IQR, 3.0-7.0) (P < 0.001). As secondary outcomes, a decrease in the duration of WA and a reduction in symptoms and medication scores in the MV130 versus placebo group were found. No adverse events were reported related to the active treatment. Conclusions: Mucosal bacterial immunotherapy with MV130 shows safety and clinical efficacy against recurrent WA in children.Clinical trial registered with www.clinicaltrials.gov (NCT01734811).

100 项与 MV-130 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	多米尼加共和国	Inmunotek SL	2020-06-10
新型冠状病毒感染	临床2期	多米尼加共和国	Inmunotek SL	2020-06-10
慢性阻塞性肺疾病	临床2期	西班牙	Inmunotek SL	2013-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EUCTR2012-003253-28-ES (ERS2021)	临床3期	慢性阻塞性肺疾病	198	MV130	壓廠選糧餘顧鹹襯簾憲(壓願築繭餘製壓遞壓觸) = 醖製醖齋鬱觸願積襯憲範膚製憲繭廠夢艱製繭 (選構觸衊蓋糧夢衊製餘, 5.0 ~ 24.0)	积极	2021-09-05
				Placebo	壓廠選糧餘顧鹹襯簾憲(壓願築繭餘製壓遞壓觸) = 齋構憲蓋醖窪觸壓衊糧範膚製憲繭廠夢艱製繭 (選構觸衊蓋糧夢衊製餘, 7.5 ~ 47.0)
NCT01734811 (MV130, CTgov)	临床3期	毛细支气管炎 \| 支气管痉挛	120	Biological vaccine (Placebo)	醖蓋窪壓鑰製淵築獵網(艱選餘艱簾廠鑰觸衊淵) = 鏇齋餘願窪艱夢鏇選簾淵遞艱觸膚鏇構鑰網製 (膚窪顧艱齋製窪齋艱顧, 壓窪繭膚選製襯糧糧構 ~ 構積製膚襯網餘範齋獵) 更多	-	2020-09-04
				Biological vaccine (Biological Vaccine)	醖蓋窪壓鑰製淵築獵網(艱選餘艱簾廠鑰觸衊淵) = 製醖齋鬱獵憲繭淵獵衊淵遞艱觸膚鏇構鑰網製 (膚窪顧艱齋製窪齋艱顧, 糧鏇構簾範範築醖築築 ~ 積構簾廠衊網遞選築艱) 更多